In 2018, product launches and growth in International sales enabled Teligent to post a group sales rise of almost a tenth to US$65.9 million, despite price erosion and serialization requirements impacting the business. Teligent expects its expanded US manufacturing facility in Buena, New Jersey, to be inspected by the FDA in the first half of 2019, with its first injectable to be launched from the site by the end of the year.
Teligent’s group sales rose by 9% to US$65.9 million in 2018 as the firm said it “enjoyed robust growth” that was “fueled by product launches and our international operations”. International sales soared by over half, while US topical turnover climbed by nearly a fifth.
“Clearly, price erosion has been a common theme over the past couple of years,” president and chief executive officer Jason...